Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
admin Pfizer and German partner BioNTech said Monday they’re seeking Food and Drug Administration authorization for…
Read MoreBiopharmaceuticals
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
Pfizer and German partner BioNTech said Monday they’re seeking Food and Drug Administration authorization for…
Read MoreMarket rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff
At least two initial public offerings were withdrawn during Tuesday’s brutal stock market rout, casting…
Read MoreReport finds Americans with long COVID losing billions in wages, as Moderna sues Pfizer and BioNTech over mRNA patents
Some 16 million Americans of working age have long-term COVID and as many as 4…
Read MoreNovartis to spin off, list Sandoz business
Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as…
Read MoreOmicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day,…
Read MorePfizer and BioNTech say data show COVID vaccine has more than 70% efficacy in small children, with cases now rising in just 7 states
Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in…
Read MoreEnhertu significantly delayed breast cancer progression in trial, AstraZeneca says
AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in…
Read MoreOpinion: There are three reasons health care is the market’s best sector today. These eight stocks are the most worry-free.
You’re tempted to increase exposure to stocks because of the market’s strength. But you’re still…
Read More
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.’s PFE, +0.45% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, -0.02% is…
Read More